Outgoing FDA Commissioner Robert Califf expressed concerns today about the risks posed by compounded versions of popular weight loss drugs, particularly those sold online. He emphasized that current laws and regulations are insufficient to safeguard Americans from these dangers.
Speaking at a media roundtable, Califf stated that the issue could be less severe if the original weight loss drugs were more affordable. “I’m very worried about the internet compounding industry. While some products may be of high quality, it’s difficult to know exactly what you’re getting when buying online,” he said. Califf, who will leave his post when President-elect Donald Trump takes office, noted that the high prices of FDA-approved weight loss drugs contribute to the problem.
Weight loss drugs from companies like Novo Nordisk and Eli Lilly can cost over $1,000 for a month’s supply. In contrast, compounded versions of these drugs are typically priced at a few hundred dollars.
Califf also called for more support for the FDA, a point that contrasts with statements made by Trump’s nominee for health secretary, Robert F. Kennedy Jr. Kennedy had criticized the FDA’s division responsible for nutrition labels, claiming it was not adequately protecting Americans. Califf responded, “The food side is massively underfunded, and if you plan to radically change the food system, that will create further issues.”
